Linked Life Data

8119423

Source:http://linkedlifedata.com/resource/pubmed/id/8119423

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1994-4-4
pubmed:abstractText
Following cataract extraction, the intraocular inflammatory response is particularly marked in some patients, who then require more intensive post-operative care. This prospective randomised double-masked controlled trial of 246 patients undergoing cataract extraction assessed the efficacy and safety of a prophylactic subconjunctival injection of betamethasone (Betnesol, Glaxo) in improving the post-operative course. Betamethasone injected subconjunctivally at the end of cataract extraction significantly reduces anterior segment inflammation (p < 0.05) on the first post-operative day. It also reduces the need for additional steroid treatment and in-patient stay (p < 0.05). The benefits are most marked in those patients prone to a greater inflammatory response: especially those with previous intraocular inflammation (p < 0.01), but also those with racial pigmentation or difficult surgery. There was no evidence of adverse effects following betamethasone; in particular there was no endophthalmitis or steroid-induced elevation of intraocular pressure. We therefore conclude that subconjunctival injection of betamethasone is a practical, safe and effective means of improving the quality and efficiency of patient care.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0950-222X
pubmed:author
pubmed:issnType
Print
pubmed:volume
7 ( Pt 6)
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
744-8
pubmed:dateRevised
2009-11-3
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Subconjunctival betamethasone is of benefit after cataract surgery.
pubmed:affiliation
Department of Ophthalmology, Greenwich District Hospital, London, UK.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial